Excellent response to pasireotide therapy in an aggressive and dopamine-resistant prolactinoma - commentary.

Excellent response to pasireotide therapy in an aggressive and dopamine-resistant prolactinoma - commentary.
Eur J Endocrinol. 2019 Jun 01;:
Authors: Raverot G, Vasiljevic A, Jouanneau E, Lasolle H
Abstract
Recent publications suggested that pasireotide could be a good therapeutic option in some dopamine resistant or aggressive prolactinomas. We discussed the 2 published cases and describe another case of poorly-differentiated plurihormonal PIT-1 positive adenoma with moderate SSTR2 expression and intense STTR5 expression succeffuly treated with PAS-LAR 40mg/month.
PMID: 31167164 [PubMed - as supplied by publisher]

Source: European Journal of Endocrinology - May 31, 2019 Category: Endocrinology Authors: Raverot G, Vasiljevic A, Jouanneau E, Lasolle H Tags: Eur J Endocrinol Source Type: research